Article Text

PDF
Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment
  1. J M Meijer1,
  2. J Pijpe1,
  3. A Vissink1,
  4. C G M Kallenberg2,
  5. H Bootsma2
  1. 1
    Departments of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  2. 2
    Departments of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  1. J M Meijer, Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, PO-Box 30.001, 9700 RB Groningen, The Netherlands; j.m.meijer{at}kchir.umcg.nl

Statistics from Altmetric.com

We previously reported that B cell depletion therapy with rituximab (4 weekly infusions of 375 mg/m2, premedication: 25 mg prednisolone intravenously) in eight patients with early primary Sjögren syndrome (pSS) and seven patients with mucosa-associated lymphatic tissue (MALT)/pSS was effective in reducing subjective and objective symptoms after 12 weeks of follow-up.1 Three patients with early pSS developed serum sickness-like disease, of whom one patient declined to further participate. The MALT component of six of the seven patients with MALT/pSS was initially effectively treated with rituximab, one of these six patients was successfully retreated 9 months after the first treatment and all six patients are …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.